NEUROGENE INC (NGNE)
(Delayed Data from NSDQ)
$48.59 USD
+4.18 (9.41%)
Updated Oct 4, 2024 04:00 PM ET
After-Market: $48.35 -0.24 (-0.49%) 7:58 PM ET
3-Hold of 5 3
F Value D Growth D Momentum F VGM
Price, Consensus and EPS Surprise
NGNE 48.59 +4.18(9.41%)
Will NGNE be a Portfolio Killer in October?
Zacks Investment Research is releasing its prediction for NGNE based on the 1-3 month trading system that more than doubles the S&P 500.
About Price, Consensus and EPS Surprise
The Price, Consensus and EPS Surprise chart displays the company's stock price along with the consensus estimate and the EPS surprise. Zacks tracks individual sell-side analyst estimates and creates a consensus EPS estimates. The consensus estimate is the average of all the current estimates made available by brokerage analysts. Consensus estimates are more advantageous because they reduce the risk of any single analyst making an incorrect forecast. ZACKS CONSENSUS ESTIMATE = THE AVERAGE OF ALL CURRENT EPS ESTIMATES. EPS Surprise is the difference (expressed as a percentage) between the actual reported quarterly earnings per share (EPS) vs the estimated quarterly EPS. A company that reports $1.10 in actual quarterly EPS vs. $1.00 in estimated quarterly EPS would show a 10% positive EPS surprise. ((Actual EPS - Estimated EPS) / absolute Estimated EPS) *100 = EPS Surprise %.
Other News for NGNE
Commit To Purchase Neurogene At $25, Earn 16% Using Options
Video: Wednesday's ETF Movers: DWAS, LIT
BlackRock Health Sciences Term Trust Q2 2024 Commentary
Three new option listings and one option delisting on August 14th
Buy Rating for Neurogene: Promising Rett Syndrome Program and Strong Financial Outlook